1. Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non- small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab 
Yuan-Yuan Zhao, MD, Cong Xue, MD, Wei Jiang, MD, Hong-Yun Zhao, MD, Yan Huang, MD, Kristin Feenstra, PhD, James H. Resau, PhD, Chao-Nan Qian, MD, PhD, Li Zhang, MD 
Journal of Thoracic Oncology 
Volume 7, Issue 1, Pages (January 2012)
DOI: /JTO.0b013e f4
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Distinguishing characteristics of two types of vessels in lung adenocarcinoma corresponding to different drug response: non-small cell lung cancer (NSCLC) samples from a partial-response patient and a progressive-disease patient are presented. Two continuous sections of each tumor were immunohistochemically stained with antibodies against CD31 and CD34, respectively. Most of the undifferentiated (CD31+/CD34−) vessels have no (or a small) lumen, a thicker vessel wall, and smaller size relative to differentiated (CD34+) vessels. The undifferentiated vessel count was 80 in the field of the tumor from the partial response patient, and it was 24 in the progressive disease patient.
Journal of Thoracic Oncology 2012 7, 71-75DOI: ( /JTO.0b013e f4)
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Relationship between undifferentiated-vessel microvascular density (MVD) and tumor shrinkage (Spearman rank correlation): 16 patients with stage IIIB and IV adenocarcinoma of lung who received first-line treatment with chemotherapy plus bevacizumab were available for analyses. Chemotherapy was repeated every 21 days for 4–6 cycles, and bevacizumab was continued every 3 weeks until evidence of disease progression or unacceptable toxic effects developed.
Journal of Thoracic Oncology 2012 7, 71-75DOI: ( /JTO.0b013e f4)
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions